Large-scale testing (Phase 3)UnknownNCT04536558
What this trial is testing
Olanzapine Plus Fosaprepitant Standard Antiemetic Therapy in the Prevention of Chemotherapy-induced Nausea and Vomiting in Patients Receiving High Emetic Risk Multi-day Chemotherapy: a Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study
Who this might be right for
Solid Tumor Patients Receiving High Emetic Risk Multi-day Chemotherapy
Sun Yat-sen University 352